Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of recombinant Staphylococcus aureus vaccine in adults undergoing orthopedic surgery
ChiCTR2200066259Phase 2Completed
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Aug 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant five-antigen Staphylococcus aureus vaccine in Staphylococcus aureus infection and surgical site infection (SSI) (2 arms), sponsored by Beijing Jishuitan Hospital. Primary endpoint: Geometric mean concentration of antibodies against each antigen component in serum. Started Aug 2019; status: completed.
02
Drugs
recombinant five-antigen Staphylococcus aureus vaccine
03
Conditions
Staphylococcus aureus infectionsurgical site infection (SSI)
Beyond the preview
Go deeper on ChiCTR2200066259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066259.